-
公开(公告)号:US20180193312A1
公开(公告)日:2018-07-12
申请号:US15658719
申请日:2017-07-25
申请人: ChronoSyn, LLC
IPC分类号: A61K31/4045 , A61K31/593 , A61K31/122 , A61K31/194 , A61P19/10 , A61P15/00 , A23L33/155
CPC分类号: A61K31/4045 , A23L33/10 , A23L33/15 , A23L33/155 , A23L33/16 , A23V2002/00 , A23V2200/306 , A23V2250/7106 , A23V2250/7144 , A61K31/122 , A61K31/194 , A61K31/593 , A61P15/00 , A61P19/10 , A23V2250/1632 , A23V2250/30
摘要: The present invention is a nutraceutical formulation, intended for oral administration, comprising co-administered if not co-formulated melatonin together with at least one of strontium, Vitamin D, and Vitamin K or their analogues. The nutraceutical combination or formulation is designed to be taken by mouth within about two hours prior to bedtime, and in fact should not be taken at any other time. The combination therapy gives new and unexpectedly improved results compared to the administration of melatonin alone.